Lisinopril and Acetaminophen Interaction: What Patients and Clinicians Need to Know

Lisinopril (brand names Prinivil, Zestril) is an ACE inhibitor used for hypertension, heart failure, chronic kidney disease with proteinuria, and post-myocardial infarction management. Acetaminophen (paracetamol, brand name Tylenol and numerous generics) is a non-opioid analgesic and antipyretic. It is not an NSAID and does not meaningfully inhibit peripheral cyclooxygenase, which is the pharmacologic feature that makes it the preferred over-the-counter pain reliever for people taking an ACE inhibitor.

Can you take lisinopril and acetaminophen together?

For most adults with normal kidney function who are not taking acetaminophen at high or continuous doses, yes. This is not an FDA-flagged interaction, and it is not the interaction pharmacists worry about when they see lisinopril on a patient's list. The interaction pharmacists and cardiologists actually worry about is lisinopril plus NSAIDs (ibuprofen, naproxen, and similar drugs), because NSAIDs directly block the prostaglandin-mediated afferent arteriolar dilation the kidney relies on when an ACE inhibitor has already dilated the efferent arteriole. That combination has a well-documented association with acute kidney injury, particularly in older adults or anyone with reduced renal reserve.

Acetaminophen does not share the strong, dose-independent COX inhibition of NSAIDs at the tissue level. It is metabolized primarily by glucuronidation and sulfation in the liver, with a minor cytochrome P450 (CYP2E1) pathway responsible for the toxic metabolite NAPQI at high doses. Lisinopril, by contrast, is absorbed and excreted essentially unchanged by the kidney and is not a substrate of hepatic CYP enzymes. There is no shared metabolic pathway, so a classic pharmacokinetic drug-drug interaction is not expected between these two drugs.

The part of the interaction that is biologically plausible, and worth taking seriously in specific patients, is pharmacodynamic: at high or sustained doses, acetaminophen has been reported to have a measurable, centrally-mediated effect on prostaglandin synthesis that can produce a modest rise in blood pressure and a small effect on renal blood flow. In a patient whose kidney is already operating with reduced hemodynamic reserve because of an ACE inhibitor, chronic kidney disease, or heart failure, that added effect is the thing to monitor for, not to assume will happen.

What is established, what is plausible, and what is not established

Evidence at different levels supports different strengths of claim here, and it is worth being precise about which is which.

Established from FDA labeling and pharmacology:

• Lisinopril is not hepatically metabolized; it is cleared renally in active form.
• Acetaminophen is metabolized by glucuronidation and sulfation, with a minor CYP2E1 pathway; this does not overlap with lisinopril clearance.
• The lisinopril label identifies NSAIDs, not acetaminophen, as agents that can reduce antihypertensive effect and worsen renal function when combined with an ACE inhibitor.

Established from general nephrology and cardiology practice, reflected in guideline preference:

• Acetaminophen is generally recommended over NSAIDs as the first-line analgesic for patients on antihypertensive therapy, because NSAIDs have a stronger and more consistent effect on renal prostaglandins and blood pressure.

Plausible but not settled at the level of a precise number:

• Regular, higher-dose acetaminophen use (chronic use above standard OTC dosing) has been studied for an effect on blood pressure in hypertensive patients, with some randomized data suggesting a measurable systolic rise compared with placebo. The exact magnitude reported varies across studies, and any specific mmHg figure quoted for this effect should be checked against the primary trial before being treated as a fixed fact, since the underlying study identifiers behind such figures require direct verification.
• Whether this blood pressure effect meaningfully compounds with lisinopril's own renal hemodynamic profile in a way that changes clinical outcomes has not been demonstrated in outcome trials specific to this drug pair.

Not established:

• There is no published signal, to our knowledge, of a synergistic hepatotoxicity risk between lisinopril and acetaminophen at therapeutic doses. Lisinopril's rare hepatotoxicity is idiosyncratic and immune-mediated; acetaminophen's is dose-dependent and metabolic. These are different mechanisms, and a shared risk has not been demonstrated.
• There is no evidence that lisinopril's own dose needs adjustment because a patient is also taking acetaminophen.

Evidence-status interaction assessment

This table distinguishes between lisinopril interaction findings that clinicians can reference directly versus those requiring individualized patient assessment or additional evidence before clinical application.

Who should be more careful, and what to check

Risk is not uniform across everyone taking lisinopril. The following groups warrant a more deliberate conversation before regular (not occasional) acetaminophen use:

• Reduced kidney function (chronic kidney disease, especially eGFR under 60 mL/min/1.73m², and more so under 30). Reduced prostaglandin-mediated renal reserve means any additional COX suppression has less room to be absorbed without effect.
• Heart failure with reduced ejection fraction. Renal perfusion is already compensated by neurohormonal mechanisms that ACE inhibitors and diuretics also act on; adding another variable that touches renal prostaglandins deserves attention.
• Regular heavy alcohol use. This is primarily a hepatotoxicity concern for acetaminophen itself (alcohol induces CYP2E1, increasing NAPQI formation), separate from the lisinopril interaction, but it changes the acetable maximum dose and lowers the threshold for checking liver function with chronic use.
• Patients already near their blood pressure target. A small additional systolic rise matters more to someone at 128/78 mmHg on lisinopril than to someone at 118/72 mmHg.

For these groups, reasonable and conservative practice is to keep acetaminophen at or below 2 g per day for regular use, limit continuous daily use to short, defined courses, and check renal function (creatinine, eGFR) and blood pressure if daily use continues beyond one to two weeks. These are general principles drawn from renal pharmacology and standard OTC labeling, not a validated dosing algorithm specific to lisinopril co-administration, and individualized dosing decisions should come from the prescribing clinician or pharmacist, not from this article.

For patients with normal kidney function, no heart failure, and no heavy alcohol use who need acetaminophen for a short course (a few days for an acute pain episode), routine OTC dosing without special monitoring is standard practice.

Why acetaminophen is still favored over NSAIDs in this population

NSAIDs (ibuprofen, naproxen, and similar agents) inhibit cyclooxygenase broadly in peripheral tissue, which directly suppresses the renal prostaglandins responsible for afferent arteriolar dilation. Combined with an ACE inhibitor's effect on the efferent arteriole, this can produce a clinically meaningful drop in glomerular filtration and a rise in blood pressure within days, particularly in older adults, patients with pre-existing renal impairment, or those who are volume-depleted. This is one of the more common and better-recognized drug-interaction pathways to acute kidney injury in outpatient and hospital settings. Acetaminophen's effect on renal prostaglandins at standard doses is considerably weaker and less consistent, which is the pharmacologic basis for treating it as the safer default analgesic in patients on ACE inhibitors, a preference reflected in general hypertension management guidance. If a specific guideline statement or direct quotation is needed for a clinical document, the current edition of the relevant ACC/AHA hypertension guideline should be checked directly rather than relied on secondhand.

Blood pressure monitoring in practice

• Check baseline blood pressure before starting a course of daily acetaminophen, if the patient's control is borderline.
• Recheck blood pressure after one to two weeks of continuous acetaminophen use above standard occasional dosing.
• If systolic blood pressure rises noticeably above the patient's recent baseline during a period of regular acetaminophen use, consider acetaminophen as a contributing factor before assuming the antihypertensive regimen has failed. Reducing or stopping acetaminophen and rechecking blood pressure is a reasonable way to test this before changing the lisinopril dose.
• Do not increase the lisinopril dose in direct response to a temporary, analgesic-associated blood pressure rise. Doing so risks hypotension once the acetaminophen course ends.

Liver safety: does the combination raise hepatotoxicity risk?

Lisinopril carries a rare, labeled risk of drug-induced liver injury that is idiosyncratic rather than dose-dependent. Acetaminophen's hepatotoxicity is well characterized and dose-dependent, becoming a genuine concern well above therapeutic dosing (acute overdose territory, not standard OTC use). These are mechanistically unrelated pathways, and there is no established evidence of a synergistic hepatotoxic signal between the two drugs at therapeutic acetaminophen doses. Patients with pre-existing significant liver disease metabolize acetaminophen more slowly and should have their maximum daily dose set by their treating clinician regardless of lisinopril use.

When to seek urgent care: Acetaminophen overdose (accidental or intentional) is a medical emergency regardless of concurrent lisinopril use. Symptoms of overdose can be absent or nonspecific in the first 24 hours (nausea, malaise) before liver injury becomes apparent. Anyone who has taken substantially more than the labeled maximum dose, or who is unsure how much they have taken, should contact a poison control center or seek emergency care rather than waiting for symptoms.

Alternatives when acetaminophen is not enough

• Topical NSAIDs (such as diclofenac gel) produce much lower systemic drug exposure than oral NSAIDs and may be a reasonable option for localized joint or muscle pain when topical delivery is appropriate for the site involved. Systemic absorption is lower than with oral NSAIDs, though it is not zero, and patients with significant renal impairment should still discuss this option with their clinician.
• Non-drug approaches, physical therapy, targeted stretching, heat or ice, and corticosteroid injection for a focal joint problem, can reduce or remove the need for a systemic analgesic entirely and are worth raising before defaulting to daily oral medication.
• Other prescription analgesics (such as tramadol) carry their own distinct risk profile, including seizure threshold effects and serotonin syndrome risk in combination with certain antidepressants, and should be prescribed and monitored individually rather than substituted casually.

What to tell patients

• Acetaminophen is generally the first OTC pain reliever to reach for while on lisinopril.
• Avoid ibuprofen, naproxen, and other NSAIDs unless a prescriber has specifically approved short-term use, since these carry a more established risk of raising blood pressure and stressing the kidneys in combination with an ACE inhibitor.
• Daily or near-daily acetaminophen use for more than a week or two is worth mentioning to a prescriber or pharmacist, particularly for anyone with reduced kidney function, heart failure, or regular alcohol use, so that a dose ceiling and a monitoring plan can be set individually.
• If home blood pressure readings run higher than usual during a period of regular acetaminophen use, mention this before assuming the lisinopril dose needs to change.
• Never exceed the labeled maximum acetaminophen dose, and treat suspected overdose as an emergency.

Where major references stand

FDA labeling for lisinopril identifies NSAIDs, not acetaminophen, as the analgesic class of concern for reduced antihypertensive effect and renal risk. General hypertension and nephrology practice favors acetaminophen over NSAIDs as the default OTC analgesic for patients on ACE inhibitors. Beyond that, the size of acetaminophen's own blood-pressure and renal-prostaglandin effect at higher or chronic doses is an area where published trial estimates exist but vary, and a clinician citing a specific number should verify it against the primary study rather than a secondary summary.